Breaking News:
About Oligomerix
Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy dementia to Alzheimer’s disease.
Technology
Oligomerix’s lead candidate is a small molecule inhibitor of tau self-association that targets the beginning of the tau aggregation cascade and its progression.
Pipeline
Oligomerix’s platform includes our lead compound (OLX07010) and 2nd generation series of compounds.
